Berlin Cures GmbH
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://berlincures.de
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
- Conditions
- Long Covid
- Interventions
- Drug: BC 007 or matching placebo
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Berlin Cures GmbH
- Target Recruit Count
- 119
- Registration Number
- NCT05911009
- Locations
- 🇦🇹
Klinik Favoriten - Wiener Gesundheitsverbund, Vienna, Austria
🇦🇹Klinik Floridsdorf - Wiener Gesundheitsverbund, Vienna, Austria
🇫🇮Terveystalo Helsinki Sleep Clinic, Helsinki, Nyland And Tavastehus County, Finland
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
- Conditions
- Cardiomyopathy, DilatedAutoantibodiesHeart Failure
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Berlin Cures GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT04192214
- Locations
- 🇷🇸
Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia
🇷🇸Zvezdara Clinical and Hospital Centre, Belgrade, Serbia
🇷🇸Bežanijska Kosa Clinical and Hospital Centre, Belgrad, Serbia
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Berlin Cures GmbH
- Target Recruit Count
- 74
- Registration Number
- NCT02955420
- Locations
- 🇩🇪
PAREXEL International GmbH, Early Phase Clinical Unit Berlin, Berlin, Germany